Opendata, web and dolomites

Immune-Image SIGNED

Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Immune-Image project word cloud

Explore the words cloud of the Immune-Image project. It provides you a very rough idea of what is the project "Immune-Image" about.

broadly    treatment    conduct    imaging    diverse    platform    join    optimal    benefit    flourishing    insights    goals    technologists    smart    mri    vary    compliant    modest    rate    believe    assembled    immunotherapies    biomarkers    body    backgrounds    forces    decisions    medical    trials    models    patients    assessing    optical    pharmacists    chemists    invasive    assure    efficient    physicists    create    gained    immune    disease    vivo    input    disciplinary    specialists    sustainable    immunotherapeutics    contribution    immunologists    clinical    international    unmet    cancer    barely    explored    patient    treatments    monitoring    synthesise    drug    inflammatory    gmp    clinically    blood    enhanced    diseases    quantitative    good    workflows    pet    immunotracers    until    manufacturing    biologists    cell    tracers    techniques    image    tissue    modulation    regulators    status    drugs    molecular    immunotherapy    played    immunotracer    personalized    emerged    validate   

Project "Immune-Image" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 27˙200˙801 €
 EC max contribution 15˙000˙000 € (55%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-14-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2024-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 4˙079˙222.00
2    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 2˙174˙208.00
3    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 1˙930˙000.00
4    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 1˙103˙496.00
5    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 1˙041˙875.00
6    VIB BE (ZWIJNAARDE - GENT) participant 885˙000.00
7    VRIJE UNIVERSITEIT BRUSSEL BE (BRUSSEL) participant 728˙329.00
8    FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ES (BARCELONA) participant 514˙560.00
9    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 510˙000.00
10    STICHTING LYGATURE NL (UTRECHT) participant 450˙000.00
11    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 433˙310.00
12    LAWRENCIUM LEGAL BV NL (AMSTERDAM) participant 400˙000.00
13    TTOPSTART BV NL (UTRECHT) participant 400˙000.00
14    ANTAROS MEDICAL AB SE (MOLNDAL) participant 250˙000.00
15    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 100˙000.00
16    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
17    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
18    IMAGINAB, INC US (INGLEWOOD CA) participant 0.00
19    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
20    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
21    PFIZER LIMITED UK (SANDWICH) participant 0.00
22    TAKEDA DEVELOPMENT CENTRE EUROPE LTD UK (LONDON) participant 0.00

Map

 Project objective

Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a personalized approach. Blood and tissue biomarkers have played only a modest role up until now in assessing immune status in vivo and we believe that non-invasive whole body imaging will make a significant contribution in the future. Although the field of imaging (PET, MRI, Optical Imaging) is flourishing, its application to patient immune status measurement and monitoring has barely been explored. Within Immune-Image we aim to develop new immunotracers for imaging specific immune cell subsets, develop quantitative imaging workflows, validate the immunotracers pre-clinically in relevant disease models, produce the tracers in a Good Manufacturing Practice (GMP)-compliant way, and conduct smart clinical trials, including with novel tracers. To this end, insights will be gained into the optimal use of drugs and a more efficient development of immunotherapeutics. Moreover, the success rate of immunotherapy development will be enhanced since our molecular imaging platform will provide novel insights into patient immune status, which will support drug development and treatment decisions. To achieve our goals, we have assembled an experienced international multi-disciplinary consortium composed of chemists, biologists, immunologists, physicists, pharmacists, information technologists, and medical specialists with diverse and essential backgrounds who will join forces to design, synthesise, evaluate and validate immunotracers and create sustainable molecular imaging techniques that can be broadly applied in the assessment of the immune status and immune modulation of patients. There will be input from patients and regulators in order to assure optimal design and execution of immunotracer clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNE-IMAGE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNE-IMAGE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More